Company Filing History:
Years Active: 2000
Title: Lanzarotti Ennio: Innovator in Oligodeoxyribonucleotide Research
Introduction
Lanzarotti Ennio is a notable inventor based in Milan, Italy. He has made significant contributions to the field of biochemistry, particularly in the development of oligodeoxyribonucleotides. His work has implications for medical science, especially in anti-ischemic therapies.
Latest Patents
Ennio holds a patent for "Hydrolytically processed oligodeoxyribonucleotides and their applications." This invention discloses new oligodeoxyribonucleotides of animal origin, with a molecular weight ranging between 4000 and 10000 daltons. These compounds can be obtained through the fractionation of polydeoxyribonucleotides or by chemical or enzymatic depolymerization of high molecular weight deoxyribonucleic acids. The new oligodeoxyribonucleotides exhibit significant anti-ischemic activity, showcasing their potential in therapeutic applications.
Career Highlights
Lanzarotti Ennio is associated with Crinos Industria Farmacobiologica S.p.a., where he continues to advance his research. His innovative work has positioned him as a key figure in the pharmaceutical industry, particularly in the development of new therapeutic agents.
Collaborations
Ennio collaborates with notable colleagues, including Mantovani Marisa and Prino Giuseppe. Their combined expertise enhances the research and development efforts at Crinos Industria Farmacobiologica S.p.a.
Conclusion
Lanzarotti Ennio's contributions to the field of oligodeoxyribonucleotide research highlight his innovative spirit and dedication to advancing medical science. His patent reflects a significant step forward in developing new therapeutic options for anti-ischemic treatments.